(DEFUNCT) Pharmaceutical & Healthcare | Kisaco Research

(DEFUNCT) Pharmaceutical & Healthcare

Filter by:
 
Life Sciences Strategy Summit on IP & Exclusivity
7-8 Oct 2025
Munich, Germany
 
8th Annual Pet Connect USA 2025
2-4 Dec 2025
Fairmont Century Plaza, Los Angeles
This December 2-4, 2025, Pet Connect USA will showcase the most exciting innovations in the pet industry, connecting you with investors and strategic partners to improve pet health and pet owner experience.500+ senior executives and 180+ start-ups from across the petcare ecosystem will gather for 2 days of 1-2-1 networking opportunities and learnings on the biggest challenges and opportunities presenting the pet market in 2025 including:Encouraging the uptake of pet insuranceImproving affordability and access to careSecuring financial investmentInnovations in data and technology that are improving pet healthCreating sustainable and affordable pet care productsIncreasing access to and contact with pet ownersREGISTER YOUR INTEREST FOR OUR 2025 SHOW 
Filter by:
 
19 Nov 2024
Boston, USA
This is your leading phage therapy networking platform to address the critical challenges in regulation, manufacturing, investment, R&D, and commercial landscapesThe all-new agenda will focus on:Addressing the progress and need for phage therapeutic regulatory guidance including participation from the MHRA discussing standardization developments.Overcoming hurdles in phage manufacturing, developing solutions to endotoxicity and quality whilst platforming use cases of innovative technology e.g. artificial intelligence.Unparalleled opportunities to network with strategic partners, pharmaceutical companies, funders and investors to progress your business development and tackle commercial barriers.Major preclinical/clinical breakthroughs across human health, animal health, aquaculture, aquaculture, nutrition, and cosmetic industries. DOWNLOAD THE AGENDA
 
Microbiome Connect
14-16 Nov 2023
BOSTON, USA
It’s a chance for senior executives to address shared challenges around innovative therapeutic development, build meaningful partnerships, and sharpen their R&D and commercial strategies. Bringing together the whole microbiome therapeutics ecosystem – from investors and large pharmaceutical companies through to the most pioneering biotechs, academic institutions and solution providers – it delivers the business-critical information you need to make strategic decisions for your organisation through in-depth case studies and expanded networking opportunities.With recent approvals for C. difficile from Rebiotix a Ferring Company, Seres Therapeutics and BiomeBank, Microbiome Connect highlights the next wave of cutting-edge science poised to impact this field – with sessions on preclinical and clinical data alongside discussions around manufacturing and diagnostic development.
 
Clone of OCTS USA 2021
17-18 Nov 2021
Boston, USA
The Onco Cell Therapy Summit (OCTS), November 16 - 18, Boston USA, brings the industry together to share novel research, manufacturing techniques, and regulatory best practice. Each session of OCTS 2021 is dedicated to the process of translating R&D into commercially viable oncological therapies.The race for bringing the first BCMA targeting CAR-T to the market is reaching a climax and next-generation cell therapies are at the front of mind for those in both industry and research.Significant break throughs in GvHD for allogeneic treatments and in the use of alternative cell therapies mean that onco cell therapies are embedding themselves as the 5th pillar of oncology. New combination studies and manufacturing capabilities are showing even more promise for this sector, but with current treatments still having high costs of use and as there are limited patient pools, there are still challenges in both clinical and commercial use of these therapies.We’ve worked with industry partners to ensure that OCTS 2021 is dedicated to the effective translation and commercialization of research into safe and efficacious therapies and address these challenges.
 
(Old) European Protein Degradation Congress 2021
21-23 Sep 2021
VIRTUAL CONGRESS
Protein degradation has redefined the drug discovery landscape, offering a promising solution in the quest to ‘drug the undruggable’. Whilst over the past few years this field as witnessed unprecedented growth, investment, and intrigue (around €4 billion worth, to be precise), 2021 is set to be another showstopper for targeted protein degradation with 15 compounds predicted to enter the clinic by the end of the year.As we enter a new wave of drug discovery:Explore the clinical viability of protein degraders including discussions on delivery methods, optimisation strategies and DMPK & SAR parametersLearn how multispecifics that form connections between POIs and cellular machinery are expanding drug amenability of proteins in this untapped, new wave of medicine.Reach “undruggable” high-hanging fruit using chemoproteomics platforms including DNA encoded libraries and covalent ligand discovery
 
Transcription Factor Drug Development 2021
6-8 Jul 2021
VIRTUAL SUMMIT | EDT Timezone
With an increasing number of projects entering the pipeline both clinically and pre-clinically aimed at targeting "undruggable" transcription factors, the industry is ready to develop further insight into the commercialization of TF-based therapeutics within oncology and other disease settings. Harnessing functional biology and translational research to evaluate which strategies - including PPI inhibitors, TRAFTACs and RNA modulators - are most effective in targeting these elusive proteins is crucial to stay ahead of the curve!The Transcription Factor Drug Development Congress is one of a kind!For the second year running, we will bring together leading industry players within large pharma and biotech, along with expert academics in transcriptomics, epigenetics, and oncology drug discovery. With a year of virtual events under our belt, our streamlined platform will provide an open forum to facilitate the sharing of in vitro and in vivo data, as well as build a deeper understanding of transcriptional machinery to make the ‘undruggable’ druggable. Use 1-2-1 meetings, interactive roundtables and discussions as well as networking roulette to hear strategies that will help you overcome the structural biology, pharmacology, and chemical obstacles in the design and development of TF-based therapeutics. Here’s a sneak peek at our 2021 offering:Understand how chromatin remodelling machinery is involved in DNA binding of the transcriptome and use this to inform targeted epigenetic therapiesAnalyse hot-off-the-press approaches to targeting myc, STAT, p53 and more including TRAFTACs, protein degraders, CPPs and PPI inhibitorsLearn how to build effective collaborations between academic labs, biotech and pharma and get insight into transcriptome and epigenetic focused tool development
 
Personalized Nutrition 2021
28-29 Jun 2021
Virtual | EDT Timezone
Partnerships and Innovation: Driving the Personalized Nutrition Industry ForwardThe global Personalized Nutrition market is forecasted to grow to $16.6 billion USD by 2027. Increasing consumer awareness about the role of nutrition on wellbeing and immunity (in part driven by Covid-19), coupled with the rise in digital health tools, testing kits, and wearables, is exacerbating this trend. There is also increasing acceptance in the healthcare industry that the “one-size-fits-all” approach to nutrition has failed, and that personalized approaches have a critical part to play in preventative care.However, despite potential, there are still considerable challenges preventing this industry from becoming mainstream. Start-ups in this space are struggling with customer retention & feedback and proving that their products work, and CPG firms and supplement brands are still assessing how best to invest in “the personal”. This Summit will provide the perfect forum for the CEO’s and founders of innovative personalized nutrition start-ups to meet with potential partners and investors. It will bring together CPG firms, supplement brands, and start-ups who are specializing in this space, to foster further partnerships and innovation.
 
Protein Engineering Connect
27-29 Apr 2021
VIRTUAL CONGRESS | PDT TIMEZONE | CEST TIMEZONE | SGT TIMEZONE
Protein engineering has achieved huge successes over the past few years, most notably Frances Arnold being awarded the 2018 Nobel Prize in Chemistry for her work on directed evolution and DeepMind’s AlphaFold algorithm reaching astounding levels of accuracy to solve the protein structure prediction problem at CASP14 in 2020.It’s no wonder that as we enter the ‘fourth wave’ of protein engineering, a plethora of methods to enable rapid and tailored design of enzymes and other proteins are being developed. Well established service providers, innovative start-ups and new industries are recognizing the impact that biocatalysis and protein engineering has on sustainability, specificity, and stability.In response to industry need and leveraging off our content led Protein Engineering series of events in 2020, we’re launching the inaugural Protein Engineering Connect event. Delivering a platform to allow industry experts to come together, network and establish valuable business connections.
 
Women's Health Innovation Series: Fertility Innovation Summit
20 Apr 2021
VIRTUAL SUMMIT | EST Timezone
Women’s health today is under-served from innovation and clinical science standpoints with outdated practices and lack of much-needed attention from key players (incl. investors and insurers). It is imperative to develop the eco-system, shift mindsets and embrace a holistic, women-centered approach.As part of our leading Women’s Health Innovation Series, The Fertility Innovation Summit is the second instalment of our 1-day themed events throughout 2021. Take a deep-dive into the verticals that are driving change in women’s health to improve the quality and access to healthcare for women globally. Reproductive-health-supporting technologies and research advances are on the rise. The Fertility Innovation Summit will focus on how to harness such innovation’s through partnerships, investment, and collaborations to empower women’s understanding and control over their own reproductive health. The breadth of advancements in fertility will be explored from clinical research, to mental health challenges, to the role of technology and digitization to determine next steps for the continued growth of this industry.Join our leading network of biotech, medical device companies, start-ups, insurers, investors, pharma, researchers, and HCPs to drive innovation at the convergence of healthcare and technology.
 
Targeting RNA Congress 2021
15-17 Mar 2021
Virtual Summit
Targeting RNA is set to be the next big thing; 85% of human genome transcribed to RNA but only 3% translated into proteins, therefore making it an obvious target. With Risdiplam being approved by the FDA in August, and several major collaborations also being penned throughout 2020, including a $190 million deal between Arrakis and Roche, it seems like a good time to target these protein precursors. Targeting RNA 2021 will take a look at the latest techniques to analyse and predict protein structure, as well as hearing from leading researchers and industry on how to incorporate learnings from RNA biology into potent and selective ligands to help prevent, rather than treat, disease.
 
Targeting Protein Misfolding Congress
15-17 Mar 2021
Virtual Summit
With the neurological drug market now worth $86 billion, and the FDA set to reach a decision on Biogen’s Acudanimib in Spring, whether you’re focused on oncology, Alzheimer’s or ALS, it’s an exciting time to be targeting misfolding diseases.Though there are currently no therapies and cures in this area of drug discovery due to several unmet drug discovery needs. The inaugural Targeting Protein Misfolding Congress will bring together academic and industry leaders, such as Anavex, Ionis Pharmaceuticals, Wren Therapeutics, Arizona State University and University of Florida, who are building platforms to identify and validate targets in protein misfolding diseases and intrinsically disordered proteins to combat these challenges:The lack of appropriate disease models, physiological assays and blood biomarkers to evaluate translation aspects and target engagement.Delivery mechanisms to deliver small molecules and biologics across the blood brain barrier.Determining the true drivers and toxic species in protein misfolding diseases. Mapping the druggable hotspots on protein aggregates and intrinsically disordered proteins to target with small molecules.
 
24-26 Feb 2021
Virtual Congress
Join us at the International Phage Futures Congress in 2021, as we create a virtual stage upon which to initiate all-important discussions & forge partnerships between key stakeholders from all over the world. Experts in their respective fields will discuss how to translate new phage-based applications into clinical studies & beyond.Discover how you can be at the forefront of the developing phage therapy market.Network & learn from established biotech companies, emerging start-ups, leading academics, global accelerator representatives, investment firms, international healthcare organisations & regulatory bodies. Among other topics, expect to hear & participate in:Advice on how to successfully navigate clinical trial progression to prove efficacy along with recent developments from leading biotechs in phage therapeutic trials targeting chronic & acute illnesses.Regulatory discussions between international governing bodies with region specific follow-up conversations with the experts.Insights into new fields for phage application, such as oncology, diagnostics & microbial gene therapy.Expert advice on how to find & secure financial investments.
 
Clone of Phage Futures 2021
24-26 Feb 2021
Virtual Congress
Join us at the International Phage Futures Congress in 2021, as we create a virtual stage upon which to initiate all-important discussions & forge partnerships between key stakeholders from all over the world. Experts in their respective fields will discuss how to translate new phage-based applications into clinical studies & beyond.Discover how you can be at the forefront of the developing phage therapy market.Network & learn from established biotech companies, emerging start-ups, leading academics, global accelerator representatives, investment firms, international healthcare organisations & regulatory bodies. Among other topics, expect to hear & participate in:Advice on how to successfully navigate clinical trial progression to prove efficacy along with recent developments from leading biotechs in phage therapeutic trials targeting chronic & acute illnesses.Regulatory discussions between international governing bodies with region specific follow-up conversations with the experts.Insights into new fields for phage application, such as oncology, diagnostics & microbial gene therapy.Expert advice on how to find & secure financial investments.
 
Women's Health Innovation Series: Contraception Summit
23 Feb 2021
VIRTUAL SUMMIT | PDT Timezone
Women’s health today is under-served from innovation and clinical science standpoints with outdated practices and lack of much-needed attention from key players (incl. investors and insurers). It is imperative to develop the eco-system, shift mindsets and embrace the holistic women-centred approach.As part of our leading Women’s Health Innovation Series, The Contraception Innovation Summit is the first instalment of our 1-day themed events throughout 2021. Take a deep-dive into the verticals that are driving change in women’s health to improve the quality and access to healthcare for women globally. Innovation in the contraception industry is long overdue. Women's desire to take ownership over their birth control, demanding more choice, safety, efficacy and education has become a vehicle for innovation and investment in this space.The Contraception Summit is about putting women at the centre of contraceptive research, innovations, and education to improve women’s contraceptive journeys throughout their lives. Join our leading network of pharma, biotech, medical device companies, start-ups, investors, researchers, and HCPs to drive innovation at the convergence of healthcare and technology.
 
WOMEN IN TARGETING THE UNDRUGGED
16-24 Feb 2021
VIRTUAL CONGRESS | EST TIMEZONE
The targeted protein degradation field is expanding, gone are the days of simple proof of concept…. We now have LYTACs, AUTACs and ATTECs as well as numerous PROTAC and Molecular Glue companies with millions of dollars worth of investment. C4 netted $182.4 million in IPO, and Nurix and Kymera closed funding with $120 million and $102 million apiece. With several start-ups launching, including Lycia and Amphista therapeutics, investment in this area is booming, and it’s not slowing down.There are currently over 85 degraders being considered at various stages of development, both preclinical and clinical, as well as in discovery. However, key questions are yet to be answered:How will degrader research translate in the clinic?Why are we still struggling with oral bioavailability?How can we effectively validate novel targets and degrade ‘undruggable’ targets of interest?What can be learned from the new, emerging degrader strategies that are emerging?Once again bringing together leaders from pharma, biotech and academia as well as innovative service providers, the North American Protein Degradation Congress is back to give you the full picture from molecular biology right the way up to the latest in medicinal chemistry and clinical data.Learn to create clinically applicable degraders to the entire proteome at the digital North American Protein Degradation Congress 2021.
 
Protein Engineering Congress EU 2020
24 Nov 2020-1 Dec 2020
Virtual Congress
Most enzymes found in nature are not suitable for industrial purposes. The field of protein and enzyme engineering is growing at a rapid rate, with competition within industries high and the need to optimise performance greater than ever. The global enzymes market size was valued at $9.9 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 7.1% from 2020 to 2027.With pharmaceutical, flavour & fragrance, consumer goods, animal feed, and agrochemical sectors all approaching the design, build and generation of new biocatalysts and molecules not found in nature, come and learn from our line-up of leading speakers to get an update on the new technologies used in the field of strain and protein engineering.The 2nd Annual European Protein Engineering Congress, dedicated to uncovering the new and emerging practices, techniques and methods of protein and enzyme engineering across industries, will return 24th-25th November and 1st December 2020. What’s new for 2020?On 24th-25th November, we will once again deliver case studies from the industry along with content on directed evolution, novel API development, AI & machine learning, and computational approaches for enzyme discovery.What’s happening 1st December?This year’s Protein Engineering Congress will be delivered virtually. Therefore we will be making all content shown on 24th-25th November on-demand, allowing you time to dissolve and digest the content ready for the third day on 1st December, which will deliver in-depth discussions on industry challenges, dedicated time for networking and 1-2-1 meetings, exclusive roundtable discussion with industry leaders, and exciting partnership announcements from within the field.Attend and you'll be able to; increase your product pipeline, increase product efficiency and increase differentiation by meeting the experts in the biocatalysis and protein engineering space.This is not your average protein engineering congress...it's about industry, sharing knowledge and optimising your protein engineering method for the best outcomes.
 
Protein Engineering Congress USA 2020
27-29 Jul 2020
VIRTUAL CONGRESS | PDT Timezone
Most enzymes found in nature are not suitable for industrial purposes. The field of protein and enzyme engineering is growing at a rapid rate, with competition within industries high and the need to optimize performance greater than ever. The virtual Protein Engineering Congress is dedicated to uncovering the new and emerging practices, techniques and methods of protein and enzyme engineering across industries.With industry approaching the design, build, and generation of new biocatalysts and molecules not found in nature, come and learn from our line-up of leading speakers to get an update on the new technologies used in the field of strain and protein engineering.The breadth of topics discussed at this meeting will focus in on directed evolution, computational protein design, synthetic biology and white biotechnology, and applications of enzyme and protein engineering and industrial biocatalysis in the biopharmaceutical, flavor & fragrance, cosmetics, and food industries.Attend and you'll be able to:Network with key opinion leaders and acquire new customersForm collaborations with companies who are engineering proteins and enzymesMeet with new technology partners to enhance internal R&DUnderstand the new applications of engineered enzymes and learn how to scale-up to large industrial manufacture
 
OCTS 2020
7-9 Jul 2020
VIRTUAL SUMMIT | EDT Timezone
Onco Cell Therapy Summit (OCTS), formerly the CAR-T Congress, is an event that brings industry together to share novel research, manufacturing techniques and regulatory best practice. Each session of OCTS 2020 is dedicated to translating your novel data assets & IP into commercially viable oncological therapies.OCTS is a 4-track event and whilst bringing together the key decision makers for CAR-T therapies, this year’s event will have an added focus on the ground breaking science that is driving the surge of interest in harnessing alternative cell therapies in cancer treatments.With 2 of our tracks comprised of research on CAR-T and alternative cell therapies, the other pillar in rolling out these therapies is increasing the affordability of the treatments. The other two tracks will delve into best practice in commercialization and manufacturing of immuno-oncological cell therapies.Each day of the summit will conclude in plenary room panels that spin out into bespoke roundtable discussions to break down the key challenges in major topics to R&D, manufacturing and commercialization.
 
Transcription Factor Drug Development
6-9 Jul 2020
VIRTUAL SUMMIT | CEST Timezone
With an increasing number of projects entering the pipeline both clinically and pre-clinically aimed at targeting transcription factors that were previously thought to be “undruggable”, the industry is ready to develop further insight into the commercialization of TF-based therapeutics within cancer and other disease settings. With multiple strategies having entered the clinic from PPI inhibitors, modulators of TF expression, and the first PROTAC-based degraders, it could only be a matter of time before the first therapy enters the market.The inaugural Transcription Factor Drug Development Congress is the first of its kind anywhere in the world! We will bring together leading industry players within large pharma and biotech, along with expert academics in the oncology drug discovery space – providing an open forum to facilitate the sharing of in vitro and in vivo data, as well as build a deeper understanding of transcriptional machinery to make the ‘undruggable’ druggable.Expect to hear strategies to overcome the structural biology, pharmacology, and chemistry obstacles in the design and development of TF-based therapeutics by hearing real success stories in the targeting of transcription factors for therapeutic benefit.Develop further insight into targeting MYC, STAT, and other transcription factors with a role in disease. 
 
CAR-T Congress EU 2020
28-30 Jan 2020
London, United Kingdom
Be part of the movement as CAR-T Therapy shapes the future of oncology.The promise of the revolutionary oncology treatment, CAR-T therapy, has become a reality this year, with end-stage cancer patients treated on public health services across the world. As CAR-T moves into the public domain, battle has commenced in the race to effectively commercialise this ground-breaking therapy.The CAR-T Congress is bringing together leading biotechs, late-stage researchers and global pharmaceutical leaders to promote and share research that will break down barriers in R&D through novel data. In our fourth annual congress, we are introducing a new pre-day focused on NK Cell Therapy and the event will run alongside our Vein-to-Vein Congress, so you can tailor your agenda and learn more about cell therapies and their manufacturing. Having listened to the market demands, this year we will be bringing you even more industry-driven understanding of translational applications of the science that drives R&D in CAR-T. Tackle the next hurdles for allogeneic treatments by limiting graft vs host disease through the use of iPSC, and increase the efficacy of these treatments in solid tumours through combination therapies and solid tumour manipulation.Talks run by biotechs, pharma and regulatory bodies, will put you in a position to make informed decisions when commercialising your CAR-T therapy.
 
28-30 Jan 2020
London, UK
The market value for cell therapies is expected to triple in size by 2025 to $8.21 bn, with investment also having increased by 64% since 2017 to $7.6 bn. Cell therapies have a huge commercial potential however scaled manufacturing, automation, logistics, regulation, and quality control continue to be limiting factors. Before cell therapies can make a mainstream clinical impact, patient access increased and truly reach their commercial potential, these obstructions need to be improved. The Vein-to-Vein Congress will gather manufacturing, operations, site managers and logistical heads from both Biotechs and pharmaceutical companies to address these bottlenecks and facilitate the commercial manufacture of cell therapies. As the cell therapy industry shifts from manual to automated manufacturing, the Vein-to-Vein Congress will discuss the measures that leading companies have put in place to streamline their manufacturing process, scale-up over time and ensure a water-tight supply chain with tracking and trackability from cell collection to patient. 
 
26-27 Nov 2019
Frankfurt
 The Targeting RNA congress will discuss the latest advancements in modulation of RNA (splicing/non-coding/micro) directly with small molecules and through epigenetics. The meeting will showcase structures of small molecules binding to disease relevant RNA and innovations in building hit-to-lead RNA specific platforms both essential for proof-of concept.Bringing together leaders in academics and industry such as Novartis, Merck, Gotham Therapeutics and University of Cambridge, who are building platforms to identify and validate targets, in order to assess in disease relevance approaches in the relatively untapped RNA world. The meeting will also discuss translational strategies, addressing structural biology, biochemical and biophysical attributes, chemical hurdles associated with new drug discovery platforms.What to expect:Opportunities to engage with key players from biotech, pharma, and academia that are building platforms to target RNA with small molecules, modify the RNA with enzymes (epigenetics) and indirectly through protein-RNA interactions.Hear how to overcome 2D structural biology parameters from leading European RNA biologists and computational biologists and emerging European epigenetics companies.The first European translational event focusing on modifying RNA upstream regulation to enable preventive medicine instead of treating symptoms with small molecules and epitranscriptomics.A meeting bridging the gap between the key research challenges such as target identification (chemo-proteomics, 2D/3D structures) and validation (small molecule binding efficiencies, selectivity and stability) and sharing new methodologies and process for obtaining hit to lead products in the RNA space.
 
Microbiome Congress 2019
13-14 Nov 2019
London, UK
The Annual European Microbiome Congress by Kisaco Research has become a trusted learning and networking platform and a true business community for microbiologists, clinicians regulatory and industry executives who require insight into the latest in microbiome research, clinical trials and collaborative partnerships.
 
Protein Engineering Congress
12-13 Nov 2019
Frankfurt, Germany
Most enzymes found in nature are not suitable for industrial purposes. The field of protein and enzyme engineering is growing at a rapid rate, with competition within industries high and the need to optimise performance greater than ever. Introducing the European Protein Engineering Congress, dedicated to uncovering the new and emerging practices, techniques and methods of protein and enzyme engineering across industries.With pharmaceutical, flavour & fragrance, consumer goods, animal feed, and agrochemical sectors all approaching the design, build and generation of new biocatalysts and molecules not found in nature, come and learn from our line-up of leading speakers to get an update on the new technologies used in the field of strain and protein engineering. Are you tasked with API and natural product synthesis? Why not hear how the industry is applying biosynthetic pathway transfer and multi-model assembly strategies to generate new molecules for industrial purposes? Are you struggling to craft new enzymes never-before-seen in this century? Hear how ancestral sequence reconstruction, smart-library design, and computer-aided innovation can allow you to discover and generate new and stable active enzymes.Attend and you'll be able to; increase your product pipeline, increase product efficiency and increase differentiation by meeting the experts in the biocatalysis and protein engineering space.This is not your average protein engineering congress...it's about industry, sharing knowledge, and optimising your protein engineering method for the best outcomes.
 
Personalized Nutrition 2019
26-27 Jun 2019
San Francisco, CA, USA
Hyperconnected and health-focused consumers are switching their purchasing habits from a one-size-fits-all approach to personalized solutions, digital interfaces and on-demand manufacturing. The nutrition space is no exception. With increasing populations of ‘biohackers’ there is a demand to self quantify, pre-diagnose and consume only foods designed to fit your daily macros. But how does the nutrition industry provide for n=1?The Personalized Nutrition Innovation Summit showcases disruptive start ups in four main categories; biological data capture, data analysis, meal planning and supplement providers.From personalized vitamins to AI-driven meal planning, we will be discussing how to develop scalable, trackable and attainable personalized nutrition solutions.The summit brings together CEOs, CTOs, investors and founders across the nutrition industry. Attend the summit to learn how to assess the current science behind personalized nutrition, the tools to strengthen recommendations and the steps to foster partnerships in this multidisciplinary ecosystem.
 
Microbiome Invest 2019
23 May 2019
London
Microbiome Invest 2019 is dedicated to showcasing the most innovative emerging companies and academics with commercially viable research that manipulates the microbiome. Active investors and multinational nutrition and health companies will also share their knowledge and perspectives on commercialisation and discuss the most cutting-edge products and research in the microbiome space.
 
European Protein Degradation Congress
22-23 May 2019
Basel, Switzerland
“Targeted protein degradation promises to be the greatest innovation in small molecule drug discovery in the new millennium.” - Manfred Koegl, Lab Head Oncology Research, Boehringer IngelheimWith capital investment coming in fast, industry is ready to commercialise the therapeutic potential of PROTACs and molecular glues to build safe, effective targeted protein degradation products. As Arvinas conducts the groundbreaking first PROTAC clinical trials this year, it could be only be a matter of time before PROTACs and molecular glues enter the market. The European Protein Degradation Congress will bring together leading industry players within big pharma and biotech along with expert academics in the ubiquitin space - providing an open forum and facilitate the sharing of in vitro and in vivo data, as well as build a deeper mechanistic understanding of the ubiquitin pathways and techniques to make the ‘undruggable’ druggable.Expect to hear strategies to overcome the structural biology, pharmacology and chemistry obstacles associated with the discovery and development of these bi-functional and single entity molecules.
 
CAR-T Congress USA 2019
16-17 Apr 2019
Boston, USA
The CAR-T Congress gathers thought leaders from biotech, big pharma, academia and investment to address the challenges and opportunities of CAR-T therapies in both liquid and solid tumors. Discussing the potential of CARs in alternative cell types, mechanisms behind toxicity and tumor targeting, this event will provide an in depth view into this expansive area.
 
Human Biotech Animal Health 2019
9 Apr 2019
Hyatt Regency Boston Harbor, Boston, MA
Join the first ever conference connecting human biotechs with the animal health industry. Traditionally, innovation in veterinary health has come from parent human pharmaceutical R&D pipelines. Within an increasingly independent and mature animal health industry, new routes to innovation are being established. There are a multitude of exceptional technologies in the human health field that could be used in animal health, but currently there is limited contact between the two areas – this summit aims to connect the two industries.
 
20-21 Mar 2019
Boston, USA
Our speakers will explore ground-breaking developments surrounding CRISPR and utilising all genome editing tools as a therapy. It will focus on advancements to overcome ‘off targets’, delivery approaches for in vivo applications and efficacy considerations across patient diversity.CRISPR Therapeutics’ TJ Cradick and Cellectis’ Stefan Scherer will share their clinical trial experiences within therapeutic genome editing applicationsHarvard’s Richard Sherwood will share how to improve CRISPR safety by utilizing machine learningCasebia’s Abraham Scaria will offer delivery guidance to progress in vivo applicationsIn an extremely busy and exciting space it can be hard to pick out the top tool innovations to increase precision and properly discuss clinical challenges, this meeting will facilitate this. It will provide an opportunity with engage with the leading experts who are working on new platforms, leading the clinical trials and have patient insights. It is also a forum to build collaborations to create a clinically and commercially viable, effective and safe approach within gene and cell therapy medicine. ‘CRISPR medicines have the potential to transform the treatment for rare genetic and perhaps common diseases; the challenge for scientists is to demonstrate that these medicines can be both safe and effective’ – Steve Rees, VP of Discovery Biology, AstraZenecaSPEAKERS FROM 
 
CAR-T Congress EU 2019
30-31 Jan 2019
London, United Kingdom
CAR-T cell therapy has shown unparalleled success in haematological malignancies, paving the way for the field of immuno-oncology. In 2017 two therapies achieved FDA approval in the USA, and following recent approval by the EMA, it is a landmark time for the industry. Despite the huge successes there are still a number of hurdles to overcome before CAR-T can be effective in mainstream oncology beyond haematological malignancies. The European CAR-T Congress’ mission is to address the opportunities and challenges that presently face the CAR-T field, to maximise the potential of this ground-breaking therapy.Sessions include:Solid tumour targeting: overcoming the tumour microenvironmentMulti-specific & dual targeting CARsProcess development, scalability & automationAllogeneic vs Autologous: the potential of off-the-shelf therapiesPatient access, implementation & regulatory challengesAdvances in gene engineeringSafety and toxicity
 
29-30 Jan 2019
Washington DC, USA
The Phage Futures Congress will bring together peers from biotech companies and academia, along with experts from regulatory bodies, pharmaceutical companies and government institutions, to discuss how to actively progress clinical science and viable phage application routes to market. You will hear about:Regulatory guidance to achieve clinical data from Cara Fiore, FDAStrategies to access the market via the veterinary, personalized medicine and traditional pharmaceutical routesInsights into investment drivers for phage therapy from NIH and Boehringer IngelheimFacts on how to manufacture GMP phageApplications to overcome multi-drug resistance with combined approaches such as phage therapy and antibiotics "This congress has the potential to act as a catalyst to further cooperative and collaborative efforts to develop alternate Phage based approaches to the antibiotic crisis. In addition, the location in the Washington DC area will facilitate an opportunity for Government Agencies, responsible for public health, such as the NIH, FDA, USDA and DOD to participate and interact with educational research groups and biotechnology companies developing phage therapies and initiating clinical testing." - Carl Merril, Adaptive Phage Therapeutics
 
Personalised Nutrition Europe 2018
5-6 Dec 2018
London, UK
Personalised Nutrition Europe is dedicated to the innovators & disruptors in nutrition. Bringing together industry leaders with emerging companies & start-ups to discuss the potential of this growing field on public health. Meet the start-ups redefining diet, incorporating a wide range of analytics and technologies to provide insights into healthcare, and hear from global nutrition companies on how the technology revolution will impact the food industry & influence consumer trends.Personalised Nutrition Europe draws on industry leaders who discuss how to integrate existing and new types of data around health and disease to reveal informative and actionable insights. The Summit will teach you how to better acquire, understand and use your data to forge the key partnerships in this industry. Key Takaways:How can I scale up my product?How can I measure the performance of my nutritional intervention?How can I better target the consumer by understanding motivation behind nutrition choices?How can I partner with retailers and industry leaders?How do I use my data to forge partnerships in industry?How can I target my consumer better and ensure they adhere to nutritional plans?How to identify and incorporate the best science into my business?How can I produce high quality data with low cost testing?How can I improve my business strategy to capitalise on growing interest in personalisation?What policy changes do I need to consider to protect my business?
 
Microbiome Congress 2018
14-15 Nov 2018
London, UK
The Annual European Microbiome Congress by Kisaco Research has become a trusted learning and networking platform and a true business community for microbiologists, clinicians regulatory and industry executives who require insight into the latest in microbiome research, clinical trials and collaborative partnerships.
 
Personalized Nutrition Innovation Summit 2018
26-27 Jun 2018
San Francisco, CA, USA
The Personalized Nutrition Innovation Summit is dedicated to the innovators & disruptors in nutrition. Bringing together industry leaders with emerging companies & start-ups to discuss the potential of this growing field on public health. Meet the start-ups redefining diet incorporating a wide range of analytics and technologies to provide insights into healthcare, and hear from global nutrition companies on how the technology revolution will impact the food industry & influence consumer trends.5 key benefits of attending:• Enabling collaboration through dedicated networking sessions• Hear from the disruptors like Habit• Gain insight from major nutrition companies like Kellogg to understand their drivers• Understand from STYR Labs about making better babies through personalized nutrition and AI• Recognize the major consumer trends reshaping nutritionFeaturing breakthrough technologies, including:• Microbiome analytics• Genomics• Biomarkers• Biosensors & wearables• AI & Big data• Retail & eCommerce
 
Human Biotech Animal Health EU
18-19 Jun 2018
Amsterdam, The Netherlands
Join the first ever conference series connecting human biotechs with the animal health industry. Following the event's hugely successful launch in Boston, USA, Human Biotech & Animal Health Business Partnering Summit is now coming to Europe. Traditionally, innovation in veterinary health has come from parent human pharmaceutical R&D pipelines. Within an increasingly independent and mature animal health industry, new routes to innovation are being established. There are a multitude of exceptional technologies in the human health field that could be used in animal health, but currently there is limited contact between the two areas – this summit aims to connect the two industries.
 
Microbiome Invest 2018
23 May 2018
Novotel London West, London, UK
The Microbiome Invest Congress 2018 is dedicated to showcasing the most innovative emerging companies and academics with commercially viable research that manipulates the microbiome. Active investors, and multi-national nutrition and pharmaceutical companies will also share their knowledge and perspectives on commercialisation and discuss the most cutting-edge products and research in the microbiome space.
 
8-9 May 2018
Boston, USA
The influence of the microbiome on human health & disease has been a growing area of interest in recent years, however until recently the impact of the microbiome on the initiation, progression & treatment of cancer was unknown. In recent months research has uncovered the potential of the microbiome to improve cancer therapies and to be a useful tool for patient stratification and diagnostics. With a better understanding of the oncobiome there is the potential to improve patient outcomes and increase the efficacy of existing therapies and drugs.
 
CAR-T Congress USA
20-22 Mar 2018
Boston, USA
The CAR-T Congress gathers thought leaders from biotech, big pharma, academia and investment to address the challenges and opportunities of CAR-T therapies in both liquid and solid tumors. Discussing the potential of CARs in alternative cell types, mechanisms behind toxicity and tumor targeting, this event will provide an in depth view into this expansive area.
 
Human Biotech Animal Health Partnering
12-13 Mar 2018
Boston, USA
Join the first ever conference connecting human biotechs with the animal health industry. Traditionally, innovation in veterinary health has come from parent human pharmaceutical R&D pipelines. Within an increasingly independent and mature animal health industry, new routes to innovation are being established. There are a multitude of exceptional technologies in the human health field that could be used in animal health, but currently there is limited contact between the two areas – this summit aims to connect the two industries.
 
Artificial Intelligence: Transforming Pharma
21-22 Feb 2018
Boston, USA
The Artificial Intelligence: Transforming Pharma Congress will discuss AI's potential for more efficiently discovering medical trends and efficacious therapeutics and also for streamlining the development phase. We'll be sharing case studies and analysis into current AI partnerships and collaborations.
 
Combined CAR-T Congress 2018
30-31 Jan 2018
Berlin, Germany
CAR-T clinical trials have demonstrated unparalleled success achieving remission rates of up to 94% in multiple hematological malignancies…is CAR-T therapy what we’ve been waiting for?Join 18+ thought-leaders from biotech, big pharma, academia and the wider service community on 30th – 31st January 2018 at Europe’s first congress dedicated to addressing the challenges and opportunities of CAR-T therapies.Hear first-hand results from unpublished human and clinical studiesExplore the challenges of the tumour microenvironmentUnderstand how to implement a combined approach to cell therapyDiscover safety switch improvement strategiesNetwork with 100+ attendees to share knowledge and understand the commercial opportunities of CAR-TWith a 50:50 split of academia to industry, build relationships whilst being updated by 20+ amazing speakers from University Hospital of Cologne, Catapult, Cellectis and more on all of the latest developments in this exciting field. Get involved today.
 
3D Cell Models Congress
24-25 Jan 2018
Berlin, Germany
The 3D Cell Models Congress 2018 will present the latest developments and innovation in three-dimensional cell models including organoids, spheroids, and organ-on-a-chip, as well as bioprinting technologies.
 
European Microbiome Congress
27-29 Nov 2017
London, UK
The Annual European Microbiome Congress by Kisaco Research has become a trusted learning and networking platform and a true business community for microbiologists, clinicians regulatory and industry executives who require insight into the latest in microbiome research, clinical trials and collaborative partnerships.
 
Market Access for Cell & Gene Therapy
18-19 Oct 2017
London, UK
With the increase in the number of cell and gene therapies being developed and coming to market globally and the potential to revolutionise the treatment of disease, this summit will discuss strategies for pricing and contracting cell or gene therapies that will allow payers to fund these innovative and significantly beneficial therapies to result in rapid patient access.
 
Animal Health Asia 2017
18-19 Oct 2017
Grand Hyatt, Beijing, PRC
Animal Health Innovation Asia is the premier B2B conference showcasing innovative technologies within the livestock, aquaculture and companion animal health markets. Last year, over 160 senior-level executives and influencers joined us to engage with the industry and discuss financial investment, M&A and market access into Asia. Our 2017 event in Beijing had a special focus on China, with ten strategic partners from the region forming our Company Showcase - a chance for global companies to find new business partners from within China.
 
Aquaculture Innovation
27-28 Sep 2017
London, UK
The Aquaculture Innovation Summit is a new conference, as part of the Animal Health Innovation series, which focuses on showcasing and supporting innovation and sustainability initiatives in three key areas of aquaculture: farm management, nutrition and health.

What People Have Said

Sponsorship Opportunities

At Kisaco Research we bring our clients both intensively researched conference programmes and the most influential networks. Kisaco Research genuinely helps its clients set and reset their business destinations and chart their own courses.

Benefits of Attending our Events

Learn from the mistakes of your peers as much as their successes - ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

LEARN

from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

NOTE

down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest from the mistakes of your peers as much as their successes - ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

INVEST

both in your company growth and your own personal development by signing up to one of our events and get started.